GrayMatters Health

GrayMatters Health

Mental Health Care

Reimagine Mental Healthcare

About us

GrayMatters Health (GMH) is a health technology company developing and marketing solutions for treating mental disorders, based on the world’s first digital brain biomarkers. The company recently won the 2023 USA Prix Galien Best Startup award. GMH is currently deploying its FDA-cleared Prism for PTSD™ at select clinics in the USA to help patients gain control of their PTSD symptoms.

Website
http://www.graymatters-health.com
Industry
Mental Health Care
Company size
11-50 employees
Headquarters
Haifa
Type
Privately Held

Locations

Employees at GrayMatters Health

Updates

  • View organization page for GrayMatters Health, graphic

    2,388 followers

    Exercise is a powerful tool for those living with PTSD. A study published in Nature Portfolio by researchers from the University of Toronto and Kyushu University reveals that physical activity promotes neuron growth and enhances neuroplasticity, effectively rewiring the brain and aiding in the forgetting of traumatic memories. This research shows the potential of exercise in managing PTSD symptoms. What's your favorite form of exercise? Learn more about the study here: https://lnkd.in/dmgJs22T

    • No alternative text description for this image
  • View organization page for GrayMatters Health, graphic

    2,388 followers

    𝐒𝐚𝐟𝐞𝐭𝐲 𝐌𝐚𝐭𝐭𝐞𝐫𝐬 Patient safety is at the core of Prism for PTSD. Non-invasive. No re-exposure to trauma. Non-medication based. Mild, temporary side effects. 𝐒𝐚𝐟𝐞𝐥𝐲 𝐧𝐚𝐯𝐢𝐠𝐚𝐭𝐞 𝐁𝐚𝐜𝐤 𝐭𝐨 𝐁𝐞𝐭𝐭𝐞𝐫 𝐰𝐢𝐭𝐡 𝐏𝐫𝐢𝐬𝐦.

    • No alternative text description for this image
  • View organization page for GrayMatters Health, graphic

    2,388 followers

    Should Social Media Come with a Warning Label? 🚨 U.S. Surgeon General Vivek Murthy has proposed a warning label on social media platforms, highlighting their potential mental health risks. This move has sparked both praise and criticism. NYU social psychologist Jonathan Haidt supports the initiative, stating, “Yes, this is a consumer product that is unsafe.” However, Michaeline Jensen, a psychologist at the University of North Carolina, offers a nuanced perspective, noting, “The actual research evidence on this question is far from compelling to support that strong of a statement.” What are your thoughts on this evolving conversation? How can we ensure a balanced approach to digital well-being while harnessing the benefits of social media?

    • No alternative text description for this image
  • View organization page for GrayMatters Health, graphic

    2,388 followers

    Our words wield immense power, especially when it comes to mental health. Recent research highlights the impact language has on our mental health. Describing our mental states using objective, specific terms instead of stigmatizing labels can make a significant difference. This simple shift can transform how we perceive ourselves and how others perceive us. It fosters empathy, reduces stigma, and promotes a healthier conversation around mental health. Share your own phrase-swaps in the comments below and let’s continue this important conversation!

    • No alternative text description for this image
  • View organization page for GrayMatters Health, graphic

    2,388 followers

    𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐌𝐚𝐭𝐭𝐞𝐫𝐬 This is not science fiction, Prism for PTSD is neuroscience.  Connecting mental disorders to their underlying brain mechanism. 𝐅𝐨𝐫 𝐏𝐓𝐒𝐃, 𝐢𝐭'𝐬 𝐚𝐥𝐥 𝐚𝐛𝐨𝐮𝐭 𝐚𝐦𝐲𝐠𝐝𝐚𝐥𝐚 𝐚𝐜𝐭𝐢𝐯𝐢𝐭𝐲.  Read more about our clinical publications here: https://lnkd.in/dqWTUG97

    • No alternative text description for this image
  • View organization page for GrayMatters Health, graphic

    2,388 followers

    Did you know that 50% of people don't respond to trauma-focused psychotherapy? A recent meta-analysis of 114 studies provides crucial insights into this issue. The research indicates that poor response to trauma-focused psychotherapy is often linked to several factors, including: - Low brain activation to fear - Early trauma - Depression - Anger - Lack of social support Understanding that not every treatment is right for every patient is essential. At GrayMatters Health, our efforts are focused on developing new treatments that augment standard-of-care therapies and improve patient outcomes. Prism for PTSD is a self-neuromodulation device FDA cleared as an adjunctive treatment of symptoms associated with PTSD. To be used under the direction of a healthcare professional, together with other pharmacological and/or non-pharmacological interventions. Reach out to learn more!

    • No alternative text description for this image
  • View organization page for GrayMatters Health, graphic

    2,388 followers

    Throughout the day we experience many emotions and pulls towards action. In times of distress, these feelings can be especially intense and confusing, making it hard to know what action to take. Our emotional regulation system plays a crucial role in helping us manage and respond to these feelings, giving us a greater sense of control over our emotional experiences. On World Brain Day, we celebrate the incredible capabilities of our emotional regulation system to help us manage life's twists and turns. 

    • No alternative text description for this image
  • View organization page for GrayMatters Health, graphic

    2,388 followers

    Got MDMA on your mind?    In the weeks leading up to the FDA’s decision date, GMH's CEO and Co-Founder, Oded Kraft, will share his insights on the PTSD landscape.   As we navigate these pivotal moments in the evolution of mental health care and innovation, don’t miss out, and follow Oded for the opportunity to learn and engage with his industry-leading insights.

    View profile for Oded Kraft, graphic

    Co-founder, CEO and President at GrayMatters Health

    PTSD Is Personal and its Treatment Should Be Too. #PTSD is highly personal because each person’s traumatic experiences are unique. Every person has a safe place to go to when stressed – places in our minds, memories we recall, or people we rely on. For those who have experienced trauma, effectively and reliably accessing this mental safe place can be a challenge. This is where Prism comes in. Prism guides the patient on a journey to find a personal mental strategy that works when they are in stressful situations, using a biomarker associated with amygdala activity. Practicing this mental strategy makes it second nature, so that it can be called on automatically whenever needed. While various forms of psychotherapy are personal, they lack the ability to scale given their 1:1 nature*. MDMA-AT is a new form of personalized treatment, but the jury (or more accurately, the FDA) is still out, and even if/when approved, significant effort of highly trained professionals is required to guide each patient. And here’s the catch. On one hand, every #trauma is personal, unique, deserving a treatment that is personal and tailored for that person. On the other hand, treatments that can be done at scale are needed. How can we resolve this conflict between personalization and scale? More on that next week. * I strongly recommend reading Jung’s The Undiscovered Self for more on that GrayMatters Health

  • View organization page for GrayMatters Health, graphic

    2,388 followers

    The United States is experiencing a significant shortage of mental health care providers. Over 168 million Americans live in areas designated as Mental Health Professional Shortage Areas without sufficient access to mental health services. This shortage is particularly severe in rural areas, with more than half of U.S. counties without a single psychiatrist! Initiatives such as integrating mental health services into primary care settings and promoting telemedicine programs are a start, but the demand for mental health services just continues to grow. Raising awareness and talking about this disparity is the first step to making sure that all Americans have access to the mental health support that they need!

    • No alternative text description for this image

Similar pages

Funding

GrayMatters Health 4 total rounds

Last Round

Grant

US$ 2.7M

See more info on crunchbase